Verici Dx plc
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a VRCDF research report →
Price Chart
About the company
Verici Dx plc is an immuno-diagnostics developer primarily dedicated to innovations within the kidney transplantation field. It creates both prognostic (predictive) and diagnostic (identifying current conditions) assays specifically designed for kidney transplant recipients. Its developmental pipeline currently features several key tests: Clarava, a pre-transplant prognostic tool designed to assess the risk of early acute rejection.
- CEO
- Sara jane Barrington
- IPO
- 2022
- Employees
- 19
- HQ
- Penarth, TN, GB
Get TickerSpark's AI analysis on VRCDF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $6.86M
- P/E
- -0.25
- PEG
- -0.01
- P/S
- 1.59
- P/B
- 0.71
- EV/EBITDA
- -0.31
- Div Yield
- 0.00%
- Gross Margin
- 79.60%
- Op Margin
- -189.04%
- Net Margin
- -193.05%
- ROE
- -138.93%
- ROIC
- -91.21%
Latest fiscal year · YoY change
- Revenue
- $3.75M+12.2%
- Gross Profit
- $2.32M-30.5%
- Op Income
- $-6,935,897
- Net Income
- $-7,087,189-20.7%
- EPS
- $-0.01+64.4%
- OCF Growth
- -39.6%
- FCF Growth
- -35.3%
- 52W High
- $2.91
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 1.22
- RSI (14)
- 48
- Avg Volume
- 158
No earnings-call transcripts are available for VRCDF yet.
- Free Float
- 46.1%
- Shares Outstanding
- 2.29B
- Float Shares
- 1.05B
Our VRCDF coverage
Recent articles, reports, and earnings notes.
No research on VRCDF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate VRCDF report →Verici Dx gains Olink Certified Service Provider status to expand proteomics offering
proactiveinvestors.co.uk · Aug 11
Verici Dx Receives New York State Approval, Establishing Nationwide Access to Tutivia™ Kidney Transplant Rejection Test
businesswire.com · Jun 24
Verici Dx Collaborators to Present Data on Predictive Value of Tutivia™ for Acute Kidney Transplant Rejection at ATC 2026
businesswire.com · Jun 17
CORRECTING and REPLACING Verici Dx Announces Publication Validating Pre-Transplant Gene Signature Test for Predicting Early Acute Rejection in Kidney Transplant Recipients
businesswire.com · May 19
Verici Dx Announces Publication Validating Pre-Transplant Gene Signature Test for Predicting Early Acute Rejection in Kidney Transplant Recipients
businesswire.com · May 19
Verici Dx rises after passing key US laboratory accreditation audit
proactiveinvestors.co.uk · Nov 12
Verici Dx climbs on 'preferred provider' deal with US healthcare network
proactiveinvestors.co.uk · Nov 6
Verici Dx plc - Special Call
seekingalpha.com · Oct 7
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.